Frag 176-191
Also known as: HGH Fragment 176-191, hGH Fragment 176-191
At a Glance
Frag 176–191 is a synthetic peptide corresponding to amino acids 176–191 of human growth hormone (hGH). In preclinical physiology, C-terminal hGH fragments (including the 176–191 region) have been studied for metabolic effects. [PMID: 645904]
⚠️ Research Status: Frag 176–191 is not an approved medication. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
In rat studies, specific C-terminal fragments were reported to influence glucose and insulin dynamics and insulin sensitivity. [PMID: 645904]
Evidence Summary
Low Confidence Animal Study >10 YearsIn normal rats, several synthetic C-terminal fragments (including 176–191) produced short-lived hyperglycemia and more sustained hyperinsulinemia, with evidence of reduced insulin sensitivity in testing paradigms. [PMID: 645904]
Safety & Unknowns
- Human pharmacokinetics, safety, and efficacy are not established by the preclinical literature.
- Claims about body composition or “fat loss” should not be inferred from limited physiology studies.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved |
| European Union (EMA) | Not approved |
| WADA | Check current list (status may change) |
Related Compounds
- AOD-9604: Commonly described as a modified form related to Frag 176–191
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |